


Find Deals information for a product or company

The Deals content provides you with all the facts you need to make a deal, choose a partner, scout the competition, or look for your next acquisition.

Example: Find Deals information for emtricitabine.

1. Use the Quick Search tool to find the **emtricitabine** product record



2. In the product record **click the Deals tab**. Here we can clearly see information around the deals, including companies involved, countries/territories, status and the value (if available).

emtricitabine

PRODUCT KEY INSIGHTS | API MANUFACTURERS | REGULATORY FILINGS | APPROVALS | CONSTRAINT DATE FORECAST & EXCLUSIVITIES | PATENTS & SPCS | US PATENT CHALLENGES | GLOBAL LITIGATION | **DEALS** | COMPETITIVE INSIGHTS | R&D | SCIENTIFIC | LAUNCHES & PACK PRICES

US MARKET SHARE | LATAM MARKET SHARE

Deals

Filters: Partner Country/Territory | Agreement Type

Customize Columns | Export

Click to customize your column view.

Click the headings to sort by that criteria. Table sorted by Value.

Deal Title	COMPANY	PRINCIPAL COUNTRY/ TERRITORY	PARTNER COMPANY	PARTNER COUNTRY/ TERRITORY	AGREEMENT TYPE	VALUE (\$M)	DEAL START DATE	DEAL END DATE	INVOLVED PROD
Principal Company	Merck & Co. Inc.	US	Eunice Kennedy Shriver Nat...	US	Drug - Funding	1,979	17-Dec-2012	No data	emtricitabine maraviroc
Principal Country/Territory	Merck & Co. Inc.	US	Triangle Pharmaceuticals Inc	US	Drug - Manufacturing/Supply	7,012	30-Jul-2002	No data	emtricitabine lopinavir
Principal Corporate Group	Merck & Co. Inc.	Japan	Gilead Sciences Inc	US	Drug - Development/Commerci...	90	22-Mar-2005	No data	cobicistat elvitegravir
Partner Company	Gilead Sciences Inc	US	Janssen R&D (Ireland)	Ireland	Drug - Development/Commerci...	200	16-Jul-2009	No data	emtricitabine lamivudine

3. Click the Deal title to view deal details.

DEAL TITLE ⓘ ↑

NICHD to award Auritec Pharmaceuticals funding to develop intravaginal ring microbicide formulation against HIV infection

Abbott Laboratories to commercially manufacture and supply Triangle Pharmaceuticals' emtricitabine worldwide

Gilead to develop Japan Tobacco's HIV integrase inhibitor JTK-303 outside Japan

Details and Information

Deal Title

NICHD to award Auritec Pharmaceuticals funding to develop intravaginal ring microbicide formulation against HIV infection

More Information

Cortellis Competitive Intelligence

Principal Company

Auritec Pharmaceuticals Inc

Partner Company

Eunice Kennedy Shriver National Institute of Child Health & Human Development

Deal Start Date

17-Dec-2012

Agreement Type

Drug - Funding

Involved Products

emtricitabine

maraviroc

tenofovir alafenamide

Status

Active

Principal Country/Territory

US

Partner Country/Territory

US

Deal End Date

No data

Value (\$M)

1.979

Events

17-Dec-2012

- In December 2012, the Eunice Kennedy Shriver National Institutes of Child Health and Human Development (NICHD) awarded funding to Auritec Pharmaceuticals for the development of intravaginal ring microbicide formulation containing tenofovir + emtricitabine + maraviroc against HIV infection. The value of the grant was worth \$338,981.

06-Apr-2015

- In April 2015, NICHD awarded further funding of \$664,015, under grant number 2R44HD075636-02, for the project.

29-Mar-2016

- In March 2016, NICHD awarded further funding of \$637,265 under project number 5R44HD075636-03, for the project.

Sources

Auritec Pharmaceuticals Inc, "1R43HD075636-01: MICROBICIDE INTRAVAGINAL RING IND ENABLING STUDIES", NIH REPORTER, Issue: December 17, 2012

Auritec Pharmaceuticals Inc, "5R44HD075636-03: Clinical safety and pharmacokinetic studies of intravaginal rings releasing multiple antiretrovirals", NIH REPORTER, Issue: March 29, 2016

Auritec Pharmaceuticals Inc, "2R44HD075636-02: CLINICAL SAFETY AND PHARMACOKINETIC STUDIES OF INTRAVAGINAL RINGS RELEASING MULTIPLE ANTIRETROVIRALS", NIH REPORTER, Issue: April 06, 2015

For more information contact Customer Service at [LS Product Support](#)

© 2024 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.